Etranacogene Dezaparvovec Gene Therapy for Haemophilia B (hope-b): 24-month Post-hoc Efficacy and Safety Data from a Single-arm, Multicentre, Phase 3 Trial

Coppens, Michiel, Pipe, Steven W, Miesbach, Wolfgang, Astermark, Jan, Recht, Michael, van der Valk, Paul, Ewenstein, Bruce, Pinachyan, Karen, Galante, Nicholas, Le Quellec, Sandra, Monahan, Paul E, Leebeek, Frank W G, Castaman, Giancarlo, Crary, Shelley E, Escobar, Miguel, Gomez, Esteban, Haley, Kristina M, Hermans, Cedric R J R, Kampmann, Peter, Kazmi, Rashid, Key, Nigel S, Klamroth, Robert, Konkle, Barbara A, Kruse-Jarres, Rebecca, Lattimore, Susan, Lemons, Richard, Meijer, Karina, O'Connell, Niamh, Quon, Doris V, Raheja, Priyanka, Symington, Emily, Verhamme, Visweshwar, Nathan, von Drygalski, Annette, Wang, Wheeler, Allison P, White, Shanna, Young, Guy